Drawing for BU OY

USPTO serial 90323613

BU OY

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
MONINGHOFF, KIM TERESA
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BU OY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

DARREN M. GELIEBTER

DARREN M. GELIEBTER LOMBARD & GELIEBTER LLP230 PARK AVENUE, 4TH FLOOR WESTNEW YORK, NY 10169United States

Goods and services

ClassDescriptionStatusFirst use
035Electronic data collection, data processing, and data analysis, all of the foregoing for business purposes, namely, for use in connection with the collection, screening, testing, transport, distribution, and storage of human blood plasma; none of the foregoing for use in connection with Internet-based health care, telehealth, health assessment, disease diagnosis, treatment and management, medical record analysis, or health care referral services provided to patients, healthcare providers, or healthcare researchersACTIVE—
042Software as a service (SAAS) services featuring software for operating, administering and managing blood plasma collection and donation centers, and the associated compensation and incentive reward programs administered therewith; Software development for use in connection with operating, administering and managing of blood plasma donation and collection centers, and the associated compensation and incentive reward programs administered therewith; Mobile application software development for use in connection with operating, administering and managing blood plasma donation and collection centers, and the associated compensation and incentive reward programs administered therewith; Application service provider featuring application programming interface (API) software and on-line, non-downloadable software development tools for use in operating, administering and managing of blood plasma donation and collection centers and the associated compensation and incentive reward programs administered therewith; platform as a service (PAAS) featuring application programming interface (API) software and on-line, non-downloadable software development tools for operating, administering and managing blood plasma donation and collection centers, and the associated compensation and incentive reward programs administered therewith; Consultancy relating to computer software for the operation, administration, and management of blood plasma donation and collection centers, and the associated compensation and incentive reward programs administered therewith; Software subscription, namely, rental of computer software for use in connection with operating, administering and managing blood plasma donation and collection centers, and the associated compensation and incentive reward programs administered therewith; leasing and customizing white label software platform for use by blood plasma donation and collection centers; none of the foregoing for use in connection with Internet-based health care, telehealth, health assessment, disease diagnosis, treatment and management, medical record analysis, or health care referral services provided to patients, healthcare providers, or healthcare researchersACTIVE—
045Licensing of software for the operation, administration, and management of blood plasma donation and collection centers, and the associated compensation and incentive reward programs administered therewith; white label software services, namely, licensing of computer software platform to blood plasma donation and collection centers for use in association with their own branding; none of the foregoing for use in connection with Internet-based health care, telehealth, health assessment, disease diagnosis, treatment and management, medical record analysis, or health care referral services provided to patients, healthcare providers, or healthcare researchersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 29, 2025MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 29, 2025ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 2, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 28, 2025EX3GSOU EXTENSION 3 GRANTED—
Feb 28, 2025EXT3SOU EXTENSION 3 FILED—
Feb 28, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 27, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 27, 2024EX2GSOU EXTENSION 2 GRANTED—
Aug 27, 2024EXT2SOU EXTENSION 2 FILED—
Aug 26, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 1, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 29, 2024EX1GSOU EXTENSION 1 GRANTED—
Feb 29, 2024EXT1SOU EXTENSION 1 FILED—
Feb 29, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 29, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 14, 2023TMBNTTAB RELEASE CASE TO TRADEMARKS—
Jul 14, 2023OP.TOPPOSITION TERMINATED NO. 999999—
Jul 14, 2023OP.DOPPOSITION DISMISSED NO. 999999—
Jun 3, 2022OP.IOPPOSITION INSTITUTED NO. 999999—
Dec 16, 2021ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Dec 7, 2021NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 7, 2021PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 17, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 3, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 2, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 1, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 1, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 30, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 30, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 30, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 22, 2021DOCKASSIGNED TO EXAMINER—
Jan 16, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 20, 2020NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance